We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Spruce

News List

Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia americanpharmaceuticalreview
May 28, 2021
Spruce Biosciences Inc. presented data from its Phase 2 clinical trial of tildacerfont in adults with classic congenital adrenal hyperplasia (CAH) at the European Society of Endocrinology’s 23rd European Congress of Endocrinology (ECE 2021).
Spruce Biosciences Announces Positive Results from Tildacerfont Study americanpharmaceuticalreview
September 23, 2019
Spruce Biosciences announced positive results from a Phase 2a, multicenter, 12-week trial of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist ...